Published in J Urol on April 01, 1997
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate (2011) 1.58
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate (2013) 1.52
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol (2009) 1.14
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist (2012) 1.04
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther (2008) 0.99
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res (2014) 0.87
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol (2014) 0.84
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol (2008) 0.84
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids (2015) 0.84
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos (2010) 0.82
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci (2016) 0.81
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Treatment options for hormone-refractory prostate cancer. Rev Urol (2007) 0.78
High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer (2013) 0.78
Controversies in the management of advanced prostate cancer. Br J Cancer (1999) 0.76
Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Br J Cancer (2000) 0.75
Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines. Indian J Urol (2007) 0.75
Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab (2000) 11.97
Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest (1996) 4.98
Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest (1990) 3.74
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest (1994) 3.49
Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest (1997) 2.57
Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation (1997) 2.26
Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes (1992) 2.16
HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care (2001) 1.99
Vascular function, insulin resistance and fatty acids. Diabetologia (2002) 1.97
Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest (1998) 1.82
Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest (1996) 1.72
Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab (2001) 1.71
Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes (2000) 1.71
The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med (1992) 1.59
Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes (2000) 1.59
Proteolysis in skeletal muscle and whole body in response to euglycemic hyperinsulinemia in normal adults. Am J Physiol (1991) 1.50
Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care (1999) 1.46
Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation (2001) 1.34
Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation (2000) 1.32
Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects. J Clin Invest (1985) 1.32
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes (1987) 1.27
Impaired glucose tolerance. Why is it not a disease? Diabetes Care (1999) 1.18
Diabetic ketoacidosis charges relative to medical charges of adult patients with type I diabetes. Diabetes Care (1997) 1.15
Insulin-mediated vasodilation: why one's physiology could be the other's pharmacology. Diabetologia (1999) 1.10
Use of a variable tracer infusion method to determine glucose turnover in humans. Am J Physiol (1990) 1.08
Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol (2008) 0.97
Kinetics of insulin-mediated and non-insulin-mediated glucose uptake in humans. Diabetes (1990) 0.96
Dose-response relationship of insulin to glucose fluxes in the awake and unrestrained mouse. Metabolism (1999) 0.96
Effects of epinephrine on insulin-mediated glucose uptake in whole body and leg muscle in humans: role of blood flow. Am J Physiol (1992) 0.92
Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle. Diabetes (1999) 0.91
Skeletal muscle proteolysis is reduced in noninsulin-dependent diabetes mellitus and is unaltered by euglycemic hyperinsulinemia or intensive insulin therapy. J Clin Endocrinol Metab (1995) 0.90
Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus. Metabolism (1998) 0.89
Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity. Diabetes (1990) 0.89
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res (2005) 0.88
Central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action. J Clin Invest (1998) 0.87
Ultradian variations of chromogranin A in humans. Am J Physiol (1991) 0.86
Skeletal muscle metastases from pancreatic cancer. Onkologie (1988) 0.84
Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. J Clin Endocrinol Metab (1991) 0.83
Endothelial function, insulin sensitivity, and hypertension. Circulation (1997) 0.83
In vivo regulation of non-insulin-mediated and insulin-mediated glucose uptake by epinephrine. J Clin Endocrinol Metab (1987) 0.81
The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism (1987) 0.78
Lack of relationship between muscle sympathetic nerve activity and skeletal muscle vasodilation in response to insulin infusion. Diabetologia (1996) 0.76
Insulin-dependent diabetes mellitus and nitrovasodilation. Important and complex interactions. Circulation (1997) 0.76
Bladder in the sac. Clin Nucl Med (1985) 0.75
Occurrence of Bezold-Jarisch reflex during hyperinsulinemic glucose clamp. Diabetes Care (1992) 0.75
Somatostatin does not increase insulin-stimulated glucose uptake in humans. Diabetes (1987) 0.75
Magnesium deficiency enhances basal glucose disposal in the rat. Am J Physiol (1995) 0.75
Glucose and amino acid turnover in untreated gestational diabetes. Diabetes Care (1996) 0.75